Page last updated: 2024-12-08
1-phospho-5-s-methylthioribulose
Description
1-phospho-5-S-methylthioribulose (PMTR) is a key intermediate in the **methionine salvage pathway** in certain organisms, particularly bacteria. This pathway allows these organisms to efficiently recycle methionine, a crucial amino acid, by using a sulfur atom from another molecule, methylthioadenosine (MTA).
Here's why PMTR is important for research:
* **Understanding microbial metabolism:** PMTR plays a vital role in the methionine salvage pathway, which is a crucial metabolic process in many bacteria. Studying PMTR can help researchers understand the complex metabolic networks within microorganisms, particularly their ability to utilize different sulfur sources.
* **Antimicrobial drug development:** The methionine salvage pathway is essential for bacterial survival, making enzymes involved in this pathway attractive targets for antimicrobial drug development. Understanding the role of PMTR in this pathway can lead to the identification of new drug targets and the development of novel antibiotics.
* **Metabolic engineering:** PMTR is also relevant to metabolic engineering, where researchers aim to modify the metabolic pathways of organisms to produce valuable compounds or improve their characteristics. Understanding the role of PMTR in methionine metabolism can be helpful for designing more efficient and robust metabolic engineering strategies.
* **Metabolic modeling:** PMTR is a crucial molecule in understanding the complex network of biochemical reactions in organisms. Researchers can use this information to create more accurate metabolic models, which can be used to predict and optimize cellular behavior.
**In summary,** PMTR is a small but important molecule in the methionine salvage pathway. Its role in bacterial metabolism makes it a valuable target for research in various fields, including antimicrobial drug development, metabolic engineering, and metabolic modeling.
S-methyl-5-thio-D-ribulose 1-phosphate(2-) : Dianion of S-methyl-5-thio-D-ribulose 1-phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (12)
Synonym |
s-methyl-5-thio-d-ribulose 1-phosphate(2-) |
CHEBI:58548 |
5-s-methyl-1-o-phosphonato-5-thio-d-ribulose |
1-phosphomethylthioribulose |
mtru-1-p |
5-methylthio-5-deoxy-d-ribulose 1-phosphate |
1-phospho-5-s-methylthioribulose |
methylthioribulose 1-phosphate |
5-(methylthio)ribulose 1-phosphate |
1pmt-ribulose |
Q27125865 |
[(3r,4s)-3,4-dihydroxy-5-methylsulfanyl-2-oxopentyl] phosphate |
Roles (2)
Role | Description |
human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
Saccharomyces cerevisiae metabolite | Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
organophosphate oxoanion | An organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |